New drug duo targets hard-to-treat gut cancers with RAS mutation
NCT ID NCT07446270
First seen Mar 07, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a combination of two drugs (tunlametinib and an anti-EGFR antibody) in people with advanced colorectal or pancreatic cancer that has a RAS gene mutation and has not responded to standard treatments. The goal is to see if the combo can shrink tumors or slow cancer growth. About 90 adults will take part, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT FOR ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.